Dissecting polycomb complexes for enhanced fetal hemoglobin production.

Area of Science:

• Genetics and Epigenetics
• Hematology
• Molecular Biology

Background:

• Polycomb repressive complexes (PRC1 and PRC2) regulate key developmental processes, including hemoglobin switching.
• Reactivating fetal hemoglobin (HbF) is a therapeutic strategy for sickle cell disease and β-thalassemia.
• Current PRC inhibitors have limited use due to pleiotropic effects.

Purpose of the Study:

• To investigate selective perturbations of PRC1 or PRC2 components for HbF reactivation.
• To determine if HbF can be induced without complete loss of PRC function.
• To identify specific targets within PRC components for therapeutic intervention.

Main Methods:

• High-density CRISPR-Cas9 mutagenesis screen of PRC1 and PRC2 components.
• Identification and characterization of EZH2 exon 14 skipping (EZH2Δ14).
• Functional assays in erythroid cells and a mouse model of human β-globin gene switching.

Main Results:

• A specific region in the EZH2 subunit, inducing exon 14 skipping (EZH2Δ14), was identified.
• EZH2Δ14 relieves HbF repression while largely maintaining cellular fitness.
• EZH2Δ14 retains H3K27 methylation and repression of a subset of PRC target genes.
• The mechanism of EZH2 control over HbF expression was confirmed in a mouse model.

Conclusions:

• Partial disruption of PRC, specifically targeting non-enzymatic domains, can yield selective phenotypes.
• EZH2Δ14 represents a promising strategy for selective HbF induction.
• Targeting specific domains within chromatin-modifying complexes holds therapeutic potential for hemoglobinopathies.